ABBV vs VOR

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Vor Biopharma continues to present a high-risk, high-reward opportunity, demonstrating 10x growth potential within 3-5 years if key clinical milestones are met. A significant strategic pivot is evident since the last analysis, with the company now primarily focused on telitacicept for autoimmune diseases (gMG and Sjögren’s disease) via late-stage Phase 3 clinical trials, replacing its prior focus ...